Pharma

If you can’t beat ‘em, try to beat ‘em another way. On the same day the US International Trade Commission (US ITC) dropped a patent…

Despite a potential business arrangement with a fellow retinal prosthesis innovator falling apart in recent weeks, Paris-based Pixium Vision is working to stay on course…

Gyroscope Therapeutics recently raised $148 million in a Series C financing to advance the clinical development of GT005, its lead investigational gene therapy, which is…

2020 was a challenging year for ophthalmic surgeons, but an array of device and pharma developments helped them get through it, while other advances are…

In another sign of the intense interest in the category of presbyopia-correcting drops, Visus Therapeutics raised $36 million in Series A financing that will be…

With a fresh infusion of capital and a new chief operating officer steeped in regulatory affairs, Aura Biosciences has put key pieces into place to…

Michael F. Chiang, MD, who took over as director of the National Eye Institute at the close of 2020, brings a unique background as an…

Science and teamwork are important factors for companies considering acquisitions, collaborations, or partnerships in the dry eye space. That was the consensus of corporate leaders…

Gemini Therapeutics, a biotech company with a focus on precision medicine for ocular and renal disease, started trading last month on the Nasdaq Global Market…

Ten years from now, gene therapy for ocular disease will have made the shift from exclusively targeting inherited retinal diseases with very small populations, such…

What a difference a few months makes. Outlook Therapeutics’ stock price plunged last August on the heels of top-line results from the NORSE 1 clinical…